Chemotherapy/radiation therapy plus/minus lonidamine in the treatment of non-small cell lung cancer (limited disease): preliminary results.
One hundred sixteen patients with unresectable locally advanced non-small cell lung cancer (NSCLC) were accrued in a prospective randomized trial comparing (A), chemotherapy (cisplatin and etoposide [VP-16]) for two courses plus radiation therapy (30 + 20 Gy split course), followed by an additional two courses to (B), the same regimen plus the addition of lonidamine (LND). There were 93 patients evaluable for response (46 in the chemotherapy/radiation arm and 47 in the chemotherapy/radiation/LND arm). One hundred fifteen patients were evaluable for toxicity. The overall response rates, median time to progression, and median survival time were similar in both arms. For the group of patients with squamous cell histology, time to progression was 27 weeks on arm A and 38 weeks on arm B (P = 0.01). Two-year survival in the squamous cell group in arm A was 9%, in arm B, 39%. LND does not give rise to additional toxicity, although myalgia and testicular pain are characteristic side effects.
Gallo-Curcio
C
C
National Cancer Institute, Regina Elena, C. Forlanini Hospital, Rome, Italy.
Verturo
I
I
Rinaldi
M
M
Ambesi Impiombato
F
F
Del Vecchio
M R
MR
Tonachella
R
R
Tropea
F
F
Antilli
A
A
Ciottoli
G B
GB
De Gregorio
M
M
D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007191:Indazoles / Q000008:administration & dosage*; D008175:Lung Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011720:Pyrazoles / Q000008:administration & dosage*; D011897:Random Allocation; D013997:Time Factors
D007191:Indazoles; D011720:Pyrazoles; C016371:lonidamine